Full-Time

Director, BD Excellence Innovation

Updated on 8/23/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

Compensation Overview

$169.7k - $305.7k/yr

+ Annual Bonus + Potential Discretionary LTI Bonus + Potential vehicle mileage reimbursement + Potential phone-use reimbursement

Franklin Lakes, NJ, USA

Remote

The role is remote within the Franklin Lakes, New Jersey location and requires approximately 75% domestic and international travel.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Power BI
Microsoft Azure
Data Analysis

Get referred to Becton Dickinson

See people who can refer or advise you

Requirements
  • A university bachelor's degree in Sciences, Engineering, or a related field is required.
  • At least 10 years of MedTech industry experience in R&D, Innovation, or Engineering, with a proven track record of driving processes to achieve results.
  • At least 8 years of experience in a company with a continuous improvement culture where visual management, problem solving, and Kaizen are embedded in the business.
  • Extensive experience using Lean tools.
  • Strong analytical skills and background.
  • Proven cross-functional and matrixed organizational problem-solving skills.
  • Experience using Microsoft ecosystem tools such as Azure DevOps, Project, Planner, and Power BI.
  • Ability to facilitate complex cross-functional meetings and initiatives that achieve and sustain desired outcomes.
  • Excellent communication, facilitation, and training skills in person and virtually, with the ability to sustain attention, create engagement, and hold team members responsible for outcomes.
  • Proven strategic agility, growth mindset, and desire to learn quickly.
  • Ability to work through complexity, take on new challenges in a complex matrixed environment, and demonstrate success within an accelerated time frame.
  • Excellent project management skills and ability to handle multiple responsibilities and deadlines.
  • Passion for continuous improvement, measuring results, and problem solving.
  • Demonstrated success driving business impact through continuous improvement and Kaizen initiatives, particularly in commercial organizations and highly dynamic environments.
Responsibilities
  • Partner with the Senior Director, BD Excellence Innovation and R&D leaders to scale BD Excellence Innovation tools and processes globally and embed them into product development.
  • Build business-unit R&D capability and self-sufficiency by strengthening competencies that enable continuous improvement and a Kaizen culture.
  • Implement and sustain processes and digital enablement for enterprise-wide information sharing to maximize best-practice sharing, alignment, and quality across business units.
  • Champion data-driven decision-making across BD segments through coaching, training, and mentoring on best-practice methods and toolsets.
  • Engage global stakeholders to understand needs, evolve the BD Excellence Innovation ecosystem, and optimize Obeya execution as requirements and trends change.
  • Provide hands-on support to worldwide business units to solve mission-critical, cross-functional challenges and facilitate training and adoption of new Obeya deployments.
  • Establish and expand Certified Practitioner networks for Obeya, Visual Project Management, and Problem Solving, and cascade the innovation toolbox through digital or instructor-led training.
  • Track adoption and performance of deployed tools and adjust them to improve effectiveness, using bowlers, key performance indicators, and action plans to drive visibility and results.
  • Represent the Senior Director, BD Excellence Innovation in key meetings and workshops as needed and identify improvement opportunities within and outside innovation.
  • Achieve and maintain Certified Practitioner status to teach BD Excellence fundamentals, including Visual Management, Daily Management, Problem Solving Process, and Kaizen, and facilitate problem-solving and Kaizen sessions across commercial, innovation, and operations teams.
Desired Qualifications
  • Experience in R&D or an innovation field is strongly preferred.
  • Experience in a regulatory environment, including the Food and Drug Administration, or in healthcare and/or MedTech is advantageous.
  • Strong knowledge of applying change management.
  • Experience in a role requiring extensive travel to where the work is performed.
  • Proven experience succeeding as the subject matter expert.
  • Demonstrated ability to coach and mentor others to achieve desired outcomes.
  • Ability to adapt to changing business environments and needs.
  • Willingness to travel domestically and internationally as required, approximately 75%.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
  • Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
  • Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.

What critics are saying

  • FDA classified BD’s intraosseous recall Class I on August 17, 2026.
  • The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
  • Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.

What makes Becton Dickinson unique

  • BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
  • BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
  • BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
Yahoo Finance
Aug 18th, 2026
Wall Street analysts give Becton, Dickinson a 'moderate buy' rating despite 12% earnings decline forecast

Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".

PR Newswire
Aug 17th, 2026
BD names Gary Sorsher chief quality officer as Jeff Silvestri retires after 25 years

BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.

MedTech Dive
Aug 13th, 2026
BD fully enrolls trial of resorbable mesh for hernia prevention.

BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."

Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.